Latest Point Therapeutics Inc. Stories
Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
Point Therapeutics, Inc. (NASDAQ:POTP) today announced that it has successfully completed the first stage of the Company's Phase 2 clinical study in Stage IIIB/IV non-small cell lung cancer.
Word of the Day
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.
The word 'upstander' in the first sense here is a play on the word 'bystander' and the idea of 'standing up' for something.